---
title: "Biofrontera Reports Q1 2026: Revenue $10.1M, Gross Margin ~80%, Adjusted EBITDA $(3.6) M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286413013.md"
description: "Biofrontera reported Q1 2026 revenue of $10.1 million, a 17% increase year-over-year, with gross margins around 80%. The company faced an operating loss of $4.3 million and a net loss of $4.8 million, while adjusted EBITDA improved to $(3.6) million. Cash and cash equivalents stood at $6.3 million. Key highlights include FDA acceptance of a supplemental NDA for Ameluz PDT and positive Phase 3 results for actinic keratoses. A strategic transaction with Biofrontera AG improved gross margins and compliance with Nasdaq minimum bid price was regained."
datetime: "2026-05-14T12:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286413013.md)
  - [en](https://longbridge.com/en/news/286413013.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286413013.md)
---

# Biofrontera Reports Q1 2026: Revenue $10.1M, Gross Margin ~80%, Adjusted EBITDA $(3.6) M

Biofrontera reported first-quarter 2026 revenue of $10.1 million, a 17% increase year-over-year, and gross margins of approximately 80% for the quarter. The company recorded an operating loss of $4.3 million and a net loss of $4.8 million, while adjusted EBITDA improved to $(3.6) million. Cash used in operations was minimal at $70 thousand, leaving cash and cash equivalents of $6.3 million as of March 31, 2026.

**Financial Highlights**

-   Revenue: $10.1 million for Q1 2026, up ~17% versus Q1 2025 ($8.6 million).
-   Gross profit margin: Approximately 80% in Q1 2026 (compared with ~62% in Q1 2025).
-   Operating loss: $4.3 million for Q1 2026 (loss from operations).
-   Net loss: $4.8 million for Q1 2026, or $(0.41) per share.
-   Adjusted EBITDA: $(3.6) million for Q1 2026 (Adjusted EBITDA margin of (35.3)%).

**Business Highlights**

-   FDA progress: FDA completed filing review and accepted the supplemental NDA for Ameluz PDT for superficial basal cell carcinoma with a PDUFA target action date of September 28, 2026.
-   Clinical program milestones: Positive, statistically significant top-line Phase 3 results for Ameluz PDT in mild to moderate actinic keratoses on extremities, neck and trunk, meeting the primary endpoint.
-   Regulatory-enabling study: Database lock achieved for a Phase 1 pharmacokinetics study required for FDA filing on treatment fields up to 240 cm² on extremities, neck and trunk.
-   Acne program progress: Positive Phase 2b results for moderate to severe acne vulgaris showing a 58% reduction in inflammatory lesions with a 3-hour incubation Ameluz PDT protocol versus 37% with vehicle PDT (PPS).
-   Corporate and commercial updates: Strategic Transaction with Biofrontera AG implemented a new earnout structure that materially lowered cost of goods and supported expanded gross margins; Nasdaq minimum bid price compliance regained on May 6, 2026.

Original SEC Filing: Biofrontera Inc. \[ BFRI \] - 8-K - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BFRI.US](https://longbridge.com/en/quote/BFRI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BFRIW.US](https://longbridge.com/en/quote/BFRIW.US.md)

## Related News & Research

- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [UCB reports positive outcomes for bimekizumab in psoriatic arthritis](https://longbridge.com/en/news/286906544.md)
- [Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 | PALI Stock News](https://longbridge.com/en/news/286156276.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)